Investor Relations
Monterey Bio is a special purpose acquisition company (SPAC) formed for the goal of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. While we may pursue an initial business combination in any region or sector, we intend to focus our efforts on identifying a biotech company that has demonstrated success and is primed to thrive in the rapidly evolving biotech industry for our initial business combination. Our goal is to evaluate business targets that are developing or enabling development of pre-commercial therapeutic candidates across a broad array of therapeutic areas, with an initial focus on oncology and immunology.
Edgar FilingPress Releases
Monterey Bio Acquisition Corporation Announces the Separate Trading of its Common Stock and Warrants, Commencing November 22, 2021NEW YORK, Nov. 17, 2021 /PRNewswire/ — Monterey Bio Acquisition Corporation (the “Company”) announced today that, commencing November 22, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s common stock and warrants included in the units. Any units not separated will continue to trade on the […]
New York, NY, October 5, 2021 (GLOBE NEWSWIRE) – Monterey Bio Acquisition Corporation (“Monterey Bio” or the “Company”) (Nasdaq: MTRYU) today announced the closing of its previously announced initial public offering of 10,000,000 units, at a price to the public of $10.00 per unit. The Company also announced that the underwriter had exercised in full its […]
New York, NY, September 30, 2021 – Monterey Bio Acquisition Corporation (the “Company”) announced today that it priced its initial public offering of 10,000,000 units at $10.00 per unit. The units are expected to trade on The Nasdaq Stock Market LLC (“Nasdaq”) under the ticker symbol “MTRYU” beginning October 1, 2021. Each unit consists of […]